Non-invasive tests such as the BAAT (body mass index, age, alanine aminotransferase, triglycerides), the European liver fibrosis score, Fibrotest, Fibroscan, hyaluronic acid, BARD (body mass index, aspartate aminotransferase (AST):alanine aminotransferase (ALT), diabetes), non-alcoholic steatohepatitis (NASH) score, and the NAFLD fibrosis score have been developed [11], and have all been tested in individuals with NAFLD [10]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.